Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Cancer Therapies02:49

Cancer Therapies

10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

19.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective Iridium-Catalyzed Reductive Amination Inside Living Cells.

Journal of the American Chemical Society·2025
Same author

Using Classifiers To Predict Catalyst Design for Polyketone Microstructure.

Journal of the American Chemical Society·2025
Same author

Reversing Signs of Parkinsonism in a Cell Model Using Mitochondria-Targeted Organoiridium Catalysis.

Journal of medicinal chemistry·2025
Same author

Non-specific phospholipase C3 is involved in endoplasmic reticulum stress tolerance in Arabidopsis.

Journal of experimental botany·2024
Same author

A ratiometric substrate for rapid evaluation of transfer hydrogenation efficiency in solution.

Dalton transactions (Cambridge, England : 2003)·2024
Same author

Bidirectional movement of tunicamycin in Arabidopsis thaliana.

The New phytologist·2023

Related Experiment Video

Updated: Mar 9, 2026

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

6.1K

Innocent But Deadly: Nontoxic Organoiridium Catalysts Promote Selective Cancer Cell Death.

Lu Yang1, Sohini Bose1, Anh H Ngo1

  • 1Department of Chemistry, University of Houston, 4800 Calhoun Road, Houston, TX, 77004, USA.

Chemmedchem
|January 5, 2017
PubMed
Summary

Nontoxic organoiridium compounds enhance cancer cell sensitivity to platinum drugs like carboplatin. This effect is selective for cancer cells, increasing reactive oxygen species and NAD+/NADH ratios.

Keywords:
biocatalysiscancerchemosensitizationdrug discoveryiridium catalysis

More Related Videos

Selective Cell Elimination from Mixed 3D Culture Using a Near Infrared Photoimmunotherapy Technique
05:18

Selective Cell Elimination from Mixed 3D Culture Using a Near Infrared Photoimmunotherapy Technique

Published on: March 14, 2016

8.3K
An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
11:04

An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model

Published on: January 13, 2023

3.8K

Related Experiment Videos

Last Updated: Mar 9, 2026

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

6.1K
Selective Cell Elimination from Mixed 3D Culture Using a Near Infrared Photoimmunotherapy Technique
05:18

Selective Cell Elimination from Mixed 3D Culture Using a Near Infrared Photoimmunotherapy Technique

Published on: March 14, 2016

8.3K
An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
11:04

An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model

Published on: January 13, 2023

3.8K

Area of Science:

  • Medicinal Chemistry
  • Cancer Biology
  • Organometallic Chemistry

Background:

  • Platinum-based drugs are standard chemotherapy agents.
  • Developing strategies to enhance platinum drug efficacy is crucial.
  • Organoiridium complexes offer potential as novel therapeutic agents.

Purpose of the Study:

  • To investigate the chemosensitizing potential of nontoxic organoiridium complexes.
  • To determine the selectivity of iridium compounds towards cancer cells.
  • To elucidate the underlying biochemical mechanisms of iridium-mediated chemosensitization.

Main Methods:

  • Treatment of various human cancer cell lines (breast, colon, lung, etc.) and non-cancer cells with organoiridium complexes and carboplatin.
  • Quantification of the 50% growth inhibition concentration (IC50) of carboplatin.
  • Measurement of reactive oxygen species (ROS) levels.
  • Assessment of NAD+/NADH ratios in treated cells.

Main Results:

  • Organoiridium complexes selectively chemosensitize cancer cells to carboplatin, reducing IC50 by up to 30-50%.
  • Non-cancer cells exhibited resistance to the chemosensitizing effects of iridium compounds.
  • Iridium-treated cancer cells showed significantly higher ROS concentrations and NAD+/NADH ratios compared to non-cancer cells.

Conclusions:

  • Nontoxic organoiridium complexes can effectively chemosensitize diverse cancer types to platinum-based chemotherapy.
  • The observed chemosensitization is selective for cancer cells, sparing normal cells.
  • Biochemical alterations, including increased ROS and NAD+/NADH ratio, likely mediate the iridium complexes' mechanism of action via a catalytic transfer hydrogenation pathway.